HCP Live October 1, 2023
Tim Smith

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

A preventative drug list (PDL) is linked with more affordable asthma medication as well as greater use of controller medication, according to recent findings, though PDLs do not lead to differences in outcomes for clinical asthma.1

This new data was the result of a recent case-control study which aimed to assess the effects of a PDL that provides exemption from out-of-pocket cost sharing for patients’ asthma medications on adverse outcomes, on their utilization, and on their out-of-pocket expenses.

The research was viewed as invaluable, given the varying results researchers have had in examining links between...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
Arcadia Launches AI-Powered Precision Medicine Solution
AbbVie to write off $3.5B over failed schizophrenia drug
Drug Price Negotiation Requires Oversight To Protect Older Americans
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
5 questions facing emerging biotech in 2025

Share This Article